Group 1 - The core viewpoint of the news is that Aorite Pharmaceutical Co., Ltd. has seen a stock price increase of 5.04%, reaching 23.15 CNY per share, with a total market capitalization of 9.403 billion CNY [1] - Aorite Pharmaceutical, established on March 5, 1998, and listed on September 21, 2020, specializes in the research, production, and sales of specialty APIs and pharmaceutical intermediates [1] - The company's revenue composition includes 85.12% from API and intermediate sales, 11.64% from finished drug sales, 2.74% from import and export trade, and 0.50% from other sources [1] Group 2 - From the perspective of fund holdings, Aorite is a major holding in the China Life Asset Management's fund, specifically the China Life Asset Health Science Mixed A Fund (005043), which holds 210,000 shares, unchanged from the previous period [2] - The fund's net asset value proportion for Aorite is 9.07%, making it the largest holding in the fund [2] - The fund has experienced a loss of 3.61% this year, ranking 7991 out of 8088 in its category, and a loss of 4.86% over the past year, ranking 7960 out of 8057 [2]
奥锐特股价涨5.04%,国寿安保基金旗下1只基金重仓,持有21万股浮盈赚取23.31万元